Access Statistics for Paul Vincent Grootendorst

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A review of instrumental variables estimation in the applied health sciences 1 2 10 687 1 2 26 1,682
An Empirical Analysis of Milk Addiction 0 0 0 0 0 0 11 267
An Empirical Examination of the Patented Medicine Prices Review Board Price Control Amendments on Drug Launches in Canada 0 0 0 2 0 0 11 23
Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment 0 0 2 111 0 0 10 374
Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population 0 0 0 115 0 1 9 617
Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population 0 0 1 64 1 2 13 363
Does It Matter Whom and How You Ask? Inter and Intra-rater Agreement in the Ontario Health Survey 0 0 0 9 0 1 10 88
Does rising income inequality affect mortality rates in advanced economies? 1 1 1 41 1 1 8 97
Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey 0 0 0 55 1 1 10 267
Effects of 'Authorized-Generics' on Canadian Drug Prices 0 0 1 237 0 1 13 1,103
Evidence of Construct Validity for Stoke and Arthritis in a Population Health Survey 0 0 0 31 0 1 6 265
Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare 0 0 0 56 0 0 16 458
Health Utilities Index Mark 3: Evidence of Construct Validity for Stroke and Arthritis in a Population Health Survey 0 0 0 25 1 1 6 111
How should we support pharmaceutical innovation? 0 0 0 214 0 1 13 576
Intellectual Property Protection And Drug Plan Coverage: Evidence From Ontario 0 0 1 34 0 1 11 116
International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada 0 0 0 82 0 0 7 297
National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations? 0 0 0 49 0 0 10 307
National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations? 0 0 0 57 1 2 14 533
New Approaches to Rewarding Pharmaceutical Innovation 0 0 0 94 0 1 14 180
On Becoming 65 in Ontario: Effects of Provincial Drug Plan Eligibility on Utilization of Prescription Medicines 0 0 0 19 0 0 3 91
Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs 0 0 0 53 0 0 7 350
Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs 0 0 0 99 0 0 8 494
Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs 0 0 0 173 0 0 13 487
Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation? 0 0 0 200 1 1 8 589
Results of an Investigation into the Integrity of the Ontario Health Survey 0 0 0 4 1 1 7 100
The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada 0 0 0 74 1 2 18 599
The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada 0 0 0 139 1 1 6 832
The Effects of Drug Subsidies on Out-of-Poket Prescription Drug Expenditures by seniors: regional Evidence from Canada 0 0 0 29 0 3 25 586
The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs 0 0 0 107 0 0 11 996
The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume I: Summary 0 0 0 66 0 0 10 436
The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report 0 0 0 39 0 1 6 175
The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume I: Summary 0 0 0 131 1 1 10 742
The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume II: Technical Report 0 0 0 68 0 0 8 297
The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature 0 0 0 192 0 1 10 715
Variance in Pharmacare Coverage Across Canada 0 0 0 32 0 1 6 220
Total Working Papers 2 3 16 3,388 11 28 374 15,433

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British Columbia 0 0 0 37 0 1 9 152
An empirical analysis of milk addiction 0 0 0 119 0 2 14 576
Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology 0 0 0 1 0 0 11 21
Distributional effects of `general population' prescription drug programs in Canada 0 0 0 49 0 1 15 417
Distributional effects of ‘general population’ prescription drug programs in Canada 0 0 0 0 0 0 13 24
Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada 0 0 0 26 2 6 13 119
Does rising income inequality affect mortality rates in advanced economies? 0 0 0 5 0 0 19 85
Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada 0 0 1 339 0 1 13 1,622
Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator 0 0 0 4 0 0 7 239
National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations? 0 0 0 21 0 1 12 294
Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics 0 1 3 35 0 2 21 141
On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective 0 0 0 5 0 0 6 35
The cost of drug development: A systematic review 0 1 3 70 0 3 28 255
The effect of patented drug price on the share of new medicines across OECD countries 0 0 0 1 0 0 6 10
The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada 0 0 0 3 0 0 1 64
The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada 0 0 0 49 0 1 11 287
Total Journal Articles 0 2 7 764 2 18 199 4,341

Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Prescription Drug Insurance and Reimbursement 0 0 0 11 2 2 6 51
Prescription Drug Insurance and Reimbursement 0 0 0 18 0 0 13 65
Total Chapters 0 0 0 29 2 2 19 116

logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage statistics for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Örebro University School of Business.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Since October 2025, abstract view statistics are potentially heavily influenced by traffic from AI bots and tools that we could not eliminate despite our best efforts.

Statistics updated 2026-10-11